Lung Cancer Patients with Germline Mutations Detected by Next-Generation Sequencing and/or Liquid Biopsy Takehito Shukuya, MD, PhD, Sandipkumar Patel,

Slides:

Advertisements

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Advertisements

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer Haa-Na Song, MD,

An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary? Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke.

Volume 150, Issue 3, Pages e87-e91 (September 2016)

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Eisaku.

Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor Song Xu, Qingchun Zhao, Sen Wei, Yi.

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis Hugo Gortais,

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met–Amplified Adenocarcinoma of the.

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer Haa-Na Song, MD,

A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient Jong Sik Lee, MD, Jae Young Hur, PhD,

Sclerosing Pneumocytoma with Lymph Node Metastasis

Quiz Page December 2007 American Journal of Kidney Diseases

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor Alessandra Bearz, MD, Elisa.

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis Hugo Gortais,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary? Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke.

Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer: A Brief Report Tsu-Hui Shiao, MD, Yih-Leong Chang, MD, Chong-Jen Yu, MD, PhD, Yeun-Chung.

Bob T. Li, M. B. B. S. , MPH, Dara S. Ross, MD, Dara L

Multiple Lung Adenocarcinomas Associated With Von Hippel-Lindau Disease Koei Ikeda, MD, PhD, Hironobu Osumi, MD, Kentaro Matsuishi, MD, Eri Matsubara,

KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma Taylor M.

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.

An Unusual Presentation of Malignant Pleural Mesothelioma

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Small Cell Transformation and T790M Mutation as Coresistance Mechanisms for First- line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor.

Stefano Occhipinti, PhD, Jeff Dunn, PhD, Dianne L

Surgical Treatment of a Giant Symptomatic Cardiac Lipoma

Histologic Transformation in NSCLC with PD-1 therapy

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Volume 150, Issue 3, Pages e87-e91 (September 2016)

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Ritbune Prakobkit, MD, William Churk-Nam Auyeung, MD

The Addition of Chemotherapy to Radiation Therapy Improves Survival in Elderly Patients with Stage III Non–Small Cell Lung Cancer Eric D. Miller, MD,

Elizabeth B. Gottlin, PhD, Rex C. Bentley, MD, Michael J

Complete Resection of Oligorecurrence of Stage I Lung Adenocarcinoma 19 Years After Operation Dai Sonoda, MD, Masashi Mikubo, MD, Kazu Shiomi, MD, PhD,

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib Shiro Fujita, MD, PhD, Katsuhiro Masago, MD, PhD, Nobuyuki Katakami, MD, PhD,

Elderly Former Smoker with HRAS Mutant Non–Small-Cell Lung Cancer

Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon.

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Prognostic Impact of Node Involvement Pattern in Pulmonary pN1 Squamous Cell Carcinoma Patients Masayuki Nakao, MD, Junji Yoshida, MD, PhD, Genichiro.

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

An Unmet Need in the WHO 2015 Biopsy Classification: Poorly Differentiated NSCCs with Positive Neuroendocrine Markers Jules L. Derks, MD Journal of.

Aglaya G. Iyevleva, MD, PhD Journal of Thoracic Oncology

A Primer on Health Economic Evaluations in Thoracic Oncology

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Nivolumab-Induced Granulomatous Inflammation of the Pleura

Quiz Page March 2014 American Journal of Kidney Diseases

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Anu Dham, MD, Alexander M. Truskinovsky, MD, Arkadiusz Z

Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor–Resistant Non–Small Cell Lung Cancer Hiroaki Ogata,

Combined Small Cell Carcinoma of the Lung: Is It a Single Entity?

Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas Jun Fan, MD Journal of Thoracic.

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

Quiz American Journal of Kidney Diseases

Metastatic Lung Cancer to the Pancreas

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Regression of Paraneoplastic Rash after Lung Cancer Chemotherapy

A B3 Type-Thymoma in a 7-Year-Old Child with Myasthenia Gravis

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Robert Comis, MD, The Passing of a “Lung Man”

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Presentation transcript:

Lung Cancer Patients with Germline Mutations Detected by Next-Generation Sequencing and/or Liquid Biopsy Takehito Shukuya, MD, PhD, Sandipkumar Patel, MD, Kate Shane-Carson, MS, LGC, Kai He, MD, PhD, Erin M. Bertino, MD, Konstantin Shilo, MD, Gregory A. Otterson, MD, David P. Carbone, MD, PhD Journal of Thoracic Oncology Volume 13, Issue 2, Pages e17-e19 (February 2018) DOI: 10.1016/j.jtho.2017.09.1962 Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Pathological features of SCLC in a 50-year-old female never-smoker (specimens from a left upper lobe wedge resection). Hematoxylin-eosin staining (A) and immunohistochemistry for synaptophysin (B) and thyroid transcription factor-1 (C) (A–C: original magnification, ×400). Journal of Thoracic Oncology 2018 13, e17-e19DOI: (10.1016/j.jtho.2017.09.1962) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions